ALX Oncology Holdings Inc (ALXO): R&D Expense
$77.00M
Year ended 2025-12-31
$61.83M
Trailing 12 months to 2026-06-30
-7.9%
3-year compound annual growth
+21.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.00M | -33.8% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $116.37M | -17.9% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $141.79M | +44.1% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $98.40M | +63.5% | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $60.17M | +107.8% | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | $28.96M | +77.6% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $16.31M | +44.7% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $11.27M | n/a | 2021-03-18, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $77.00M | -33.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $61.98M | -47.5% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $22.84M | +180.2% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $7.98M | +10.9% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $24.61M | +29.2% |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗